New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTNCI, DYAX, BCRX, VRTS, EPE, SBNY, MGLNOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
13:43 EDTBCRXUSDA says bird flu found in backyard poultry in Oregon
The United States Department of Agriculture’s Animal and Plant Health Inspection Service confirmed the presence of highly pathogenic H5N8 avian influenza in guinea fowl and chickens from a small backyard poultry flock in Winston, Oregon. The H5N8 virus has not been found in commercial poultry anywhere in the United States and there is no immediate public health concern, as the H5N8 virus has been found in birds in other parts of the world and has not caused any human infection to date, the USDA stated. The Fly notes companies that offer or are developing flu vaccines include BioCryst (BCRX) and Novavax (NVAX). Publicly traded meat producers include Hormel Foods (HRL), Pilgrim's Pride (PPC), Sanderson Farms (SAFM) and Tyson Foods (TSN). Reference Link
December 18, 2014
08:01 EDTEPEEP Energy downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
07:21 EDTBCRXBioCryst initiates OPuS-2 clinical trial of BCX4161
Subscribe for More Information
December 17, 2014
10:51 EDTMGLNLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte provides outlook and favorite names for 2015 in the Hospitals and Managed Care Industry on an Analyst/Industry conference call to be held on December 18 at 1 pm.
December 16, 2014
12:18 EDTNCINavigant Consulting names Ed Keller as Chief Marketing Officer
Navigant announced that Edward Keller has joined the Firm as Chief Marketing Officer. As a member of Navigant’s senior leadership team, Keller will lead brand initiatives, oversee marketing for the Firm and will ensure that Navigant’s value is conveyed effectively to both internal and external stakeholders. Keller joins Navigant from Grant Thornton LLP, where he was the Head of Integrated Marketing and oversaw marketing strategy, planning and execution across all industries, regions and services.
06:36 EDTMGLNMagellan Health reaffirms FY14 guidance
The company confirmed its FY14 guidance, which was most recently updated in October. “We’ve made great progress this year on our plan for growth, primarily related to our Magellan Complete Care and Pharmacy Management initiatives,” said the company. “In MCC, we are managing the total care of individuals with complex needs. We serve those with serious mental illness in Florida, and Medicaid Managed Long Term Care recipients in New York. In our pharmacy business, we now offer full service pharmacy capabilities to manage the entire drug spend of populations for health plan, employer, and government customers. We will continue to solidify our leadership position in population health management in the coming years across our behavioral health, pharmacy and specialty solutions businesses.”
06:34 EDTMGLNMagellan Health sees FY 15 adj. EPS $3.28-$3.73, consensus $2.67
Sees FY15 revenue $4.25B-$4.49B, consensus $4.47B. Sees FY15 EPS $1.90-$2.50, inclusive of share repurchases to date. For 2015, the company is assuming weighted average shares outstanding of 26.8M. The company also expects segment profit to be in the range of $265M-$285M. Cash flow from operations is expected to be in the range of $171M-$195M.
December 15, 2014
11:09 EDTEPEEP Energy management to meet with Jefferies
Subscribe for More Information
07:17 EDTBCRXBioCryst initiates Phase 1 clinical trial of BCX4430
BioCryst Pharmaceuticals announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate intramuscular, or I.M., administration of BCX4430 in healthy volunteers. BCX4430 is being developed as a potential treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via I.M. injection in healthy subjects. In part one of the study, subjects will receive a single dose of BCX4430; in part two of the study, subjects will receive BCX4430 for seven days. Up to six single-dose cohorts and four multiple-dose cohorts will be evaluated, with a total of up to 88 volunteers participating.
December 11, 2014
10:59 EDTSBNYSignature Bank management to meet with Sterne Agee
Meeting to be held in Kansas City on December 17 and in Houston on December 18 hosted by Sterne Agee.
December 10, 2014
14:16 EDTMGLNMagellan Health to host conference call
Subscribe for More Information
09:32 EDTVRTSVirtus Investment Partners increases share repurchase authorization
Subscribe for More Information
December 8, 2014
15:03 EDTNCINavigant Consulting management to meet with Sidoti
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use